Next Steps For Interchangeable Biosimilars: Lifecycle Regulation Policy Development

US FDA seeks stakeholder views on manufacturing changes, new reference product indications and other questions that build on its draft guidance for approval of interchangeable biosimilars.

The US FDA is seeking stakeholder views on how it should regulate interchangeable biosimilars over their lifecycle, in conjunction with its new draft guidance on interchangeability.

The agency is requesting input on post-approval manufacturing changes and the impact of new reference product indications on a previously...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance